Sort   by:  
 Page size 
MetabolomicsIntegrated Multi-omics Elucidation of the Uric Acid Degradation Pathway in Limosilactobacillus fermentum M5e

Hyperuricemia is a growing global health concern associated with gout, renal diseases, and cardiovascular disorders. Current pharmacotherapies are often limited by side effects, underscoring the need for alternative strategies. In this study, we isolated Limosilactobacillus fermentum M5...

2026-01-26 | MTBLS13223 | MetaboLights
MetabolomicsLimosilactobacillus fermentum-derived 4-guanidinobutyric acid promotes intestinal urate excretion via the HNF4α-ABCG2 axis to alleviate hyperuricemia

Hyperuricemia is a prevalent metabolic illness and an established risk factor for gout and chronic renal disease. Present urate-lowering medications are often limited by side effects, highlighting the necessity for innovative strategies. The gut microbiota has a role in urate homeostasis; however...

2026-01-26 | MTBLS13637 | MetaboLights
GenomicsLimosilactobacillus fermentum
Limosilactobacillus fermentum Genome sequencing
PRJNA1118680 | ENA
GenomicsLimosilactobacillus fermentum
Limosilactobacillus fermentum Assembly
PRJNA1001634 | ENA
GenomicsLimosilactobacillus fermentum
Limosilactobacillus fermentum Assembly
PRJNA904097 | ENA
MetabolomicsLimosilactobacillus reuteri in Promoting Growth Performance and Regulating Lipid Metabolism in Zuili Black Pigs

Abstract

Background

The gut microbiota is a key regulator of host lipid metabolism. In indigenous pigs, variation in growth performance and intramuscular fat (IMF) deposition has been linked to microbiota-host interactions, yet the specific taxa and metabolites that govern host lipid ...

2025-09-20 | MTBLS13017 | MetaboLights
GenomicsLimosilactobacillus fermentum
Limosilactobacillus fermentum Genome sequencing
PRJNA1106189 | ENA
GenomicsLimosilactobacillus fermentum
Limosilactobacillus fermentum Raw sequence reads
PRJNA1120194 | ENA
ProteomicsThe use of omics technologies in creating LBP and postbiotics based on the Limosilactobacillus fermentum U-21
In recent years, there has been an increasing tendency to create drugs of various types based on certain commensal bacteria of the human microbiota and their ingredients. This primarily concerns live biotherapeutics (LBPs) and postbiotics. The creation of such drugs, which can be called pharmacobiot...
ORGANISM(S): Limosilactobacillus fermentum 
2024-06-04 | PXD050857 | Pride
Pharmabiotics Metabolome Omics technologies Limosilactobacillus fermentum u-21 Proteome Postbiotics 
GenomicsLimosilactobacillus fermentum
Limosilactobacillus fermentum Genome sequencing and assembly
PRJNA1058848 | ENA
Sort   by:  
 Page size